Assured Investment Management’s Myriad Genetics MYGN Stock Holding History

Assured Investment Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-2,133	Closed	-$98K	–	1257
2018 Q3	$98K	Buy	+2,133	New	+$94.8K	﹤0.01%	1046
2018 Q2	–	Sell	-7,877	Closed	-$233K	–	1275
2018 Q1	$233K	Buy	+7,877	New	+$267K	0.01%	945
2017 Q1	–	Sell	-1,000,000	Closed	-$16.7M	–	685
2016 Q4	$16.7M	Sell	1,000,000 -1,263	-0.1%	-$22.9K	0.31%	76
2016 Q3	$20.6M	Buy	1,001,263 +968,705	+2,975%	+$24.6M	0.47%	55
2016 Q2	$996K	Buy	32,558 +18,963	+139%	+$659K	0.02%	277
2016 Q1	$509K	Buy	+13,595	New	+$512K	0.01%	329
2014 Q3	–	Sell	-476,034	Closed	-$18.5M	–	261
2014 Q2	$18.5M	Sell	476,034 -366,719	-44%	-$13.6M	0.31%	78
2014 Q1	$28.8M	Buy	842,753 +699,594	+489%	+$21.7M	0.47%	67
2013 Q4	$3M	Sell	143,159 -419,945	-75%	-$10.6M	0.05%	180
2013 Q3	$13.2M	Buy	+563,104	New	+$16M	0.51%	60

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Assured Investment Management's MYGN Position: Q4 2018 in Review

Assured Investment Management sold out of Myriad Genetics (MYGN) in Q4 2018, closing a stake of 2,133 shares — an estimated $98K sold.

Assured Investment Management first reported a position in MYGN in Q3 2013 and held it in 10 quarters. The position peaked at $28.8M in Q1 2014. 264 funds tracked by Wall St. Rank hold MYGN as of Q4 2018.

Assured Investment Management reported no remaining Myriad Genetics position as of Q4 2018 after selling out during the quarter.
Assured Investment Management sold 2,133 Myriad Genetics shares in Q4 2018, an estimated $98K.
Assured Investment Management first reported a position in Myriad Genetics in Q3 2013 and held it in 10 quarters.
Assured Investment Management's Myriad Genetics position peaked at $28.8M in Q1 2014.
264 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2018.

Based on Assured Investment Management's 13F filing for Q4 2018, filed 13 Feb 2019.